PE20010052A1 - Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht - Google Patents

Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht

Info

Publication number
PE20010052A1
PE20010052A1 PE2000000368A PE0003682000A PE20010052A1 PE 20010052 A1 PE20010052 A1 PE 20010052A1 PE 2000000368 A PE2000000368 A PE 2000000368A PE 0003682000 A PE0003682000 A PE 0003682000A PE 20010052 A1 PE20010052 A1 PE 20010052A1
Authority
PE
Peru
Prior art keywords
alkyl
aryl
azepinindol
agonists
antagonists
Prior art date
Application number
PE2000000368A
Other languages
English (en)
Inventor
Jackson B Hester Jr
Bruce N Rogers
Eric Jon Jacobsen
Michael Dalton Ennis
Kristine E Frank
Velde Susan L Vander
Brad A Acker
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of PE20010052A1 publication Critical patent/PE20010052A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/16—Peri-condensed systems

Abstract

SE REFIERE A DERIVADOS DE 1,2,3,4,5,6-HEXAHIDROAZEPIN-[4,5-b]INDOL QUE TIENEN UN ANILLO PARA UNIR LA POSICION 6 Y 7 DE FORMULA I DONDE R1 ES OH, NITRO, HALOGENO, CN, TRIFLUOROMETILO, S(O)mNRaRb, NRcRd, S(O)mRe, ENTRE OTROS; R2 ES H, ALQUILO C1-C7, ALCANOILO C1-C7, ALCOXICARBONILO C1-C7, ENTRE OTROS; X E Y JUNTOS SON UNA CADENA CON ATOMOS DE C OPCIONALMENTE CONTIENE UN GRUPO -O-, -S-, -SO-, -SO2-, NRf OPCIONALMENTE SUSTITUIDA CON OXO, OH, ALCOXILO C1-C7; m ES 0-2; n ES 0-3; CADA Ra Y Rb SON H, ALQUILO C1-C7, ARILO, ARILALQUILO C1-C7, HETEROARILO, HETEROARIL ALQUILO C1-C7; Ra Y Rb JUNTO CON N FORMAN PIRROLIDINO, PIPERIDINO, MORFOLINO, TIOMORFOLINO; CADA Rc Y Rd SON H, ALQUILO C1-C7, ALCANOILO C1-C7, ALCOXICARBONILO C1-C7, ARILO, O JUNTO CON N FORMAN PIRROLIDINO, PIPERIDINO, MORFOLINO, TIOMORFOLINO, ENTRE OTROS; Re ES H, ALQUILO C1-C7, ARILO, ENTRE OTROS; Rf ES H, ALQUILO C1-C7, ARILO, ARILALQUILO C1-C7, ENTRE OTROS; CON LA CONDICION QUE Y NO ES OXI, TIO, SULFINILO, NRf, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 5,6,9,10,11,12-HEXAHIDRO-4H,8H-AZEPIN[4`,5':4,5]PIRROL[3,2,1-ij]QUINOLINA, 2-METIL-5,6,9,10,11,12-HEXAHIDRO-4H,8H-AZEPIN[4',5':4,5]PIRROL[3,2,1-ij]-QUINOLINA, ENTRE OTROS. LOS COMPUESTOS I SON LIGANDOS DE SEROTONINA 5-HT Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE ENFERMEDADES DEL SISTEMA NERVIOSO CENTRAL, SUENO, DEPRESION
PE2000000368A 1999-04-23 2000-04-19 Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht PE20010052A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13081199P 1999-04-23 1999-04-23

Publications (1)

Publication Number Publication Date
PE20010052A1 true PE20010052A1 (es) 2001-01-27

Family

ID=22446459

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000368A PE20010052A1 (es) 1999-04-23 2000-04-19 Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht

Country Status (20)

Country Link
EP (1) EP1173440B1 (es)
JP (1) JP2002543080A (es)
KR (1) KR20020005708A (es)
CN (1) CN1183132C (es)
AR (1) AR023574A1 (es)
AT (1) ATE276255T1 (es)
AU (1) AU760943C (es)
BR (1) BR0009983A (es)
CA (1) CA2367682A1 (es)
DE (1) DE60013803T2 (es)
DK (1) DK1173440T3 (es)
EC (1) ECSP003426A (es)
ES (1) ES2226822T3 (es)
HK (1) HK1045512B (es)
NZ (1) NZ514553A (es)
PE (1) PE20010052A1 (es)
PT (1) PT1173440E (es)
SI (1) SI1173440T1 (es)
WO (1) WO2000064899A1 (es)
ZA (1) ZA200108636B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
ES2223536T3 (es) 1999-06-15 2005-03-01 Bristol-Myers Squibb Pharma Company Gamma-carbolinas condensadas con heterociclos sustituidas.
US7071186B2 (en) 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
AU2001269781A1 (en) * 2000-07-06 2002-01-21 Pharmacia And Upjohn Company Substituted 2,3,7,8,9,10,11,12-octahydroazepino(4,5-b)pyrano(3,2-e) indoles
AR034264A1 (es) 2000-09-20 2004-02-18 Upjohn Co Derivados azepino(4,5-b)indol sustituidos y composiciones farmaceuticas
US6858604B2 (en) 2000-11-03 2005-02-22 Wyeth Cyclohepta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
US6759405B2 (en) 2000-11-03 2004-07-06 Wyeth Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
US6777407B2 (en) 2000-11-03 2004-08-17 Wyeth Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
EP1343791A2 (en) * 2000-12-20 2003-09-17 Bristol-Myers Squibb Company Substituted tetracyclic pyridoindoles as serotonin agonists and antagonists
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
US20020160999A1 (en) * 2001-01-08 2002-10-31 Jacobsen Susan Fox Substituted indolines
US20030060462A1 (en) * 2001-08-06 2003-03-27 Hoffman Robert L. Therapeutic compounds
US6720316B2 (en) * 2001-08-06 2004-04-13 Pharmacia & Upjohn Company Therapeutic 5-HT ligand compounds
WO2003024976A2 (en) * 2001-09-21 2003-03-27 Pharmacia & Upjohn Company Tricyclic indole derivatives as 5-ht ligands
EP1436294A1 (en) 2001-10-18 2004-07-14 PHARMACIA & UPJOHN COMPANY Tetracyclic azaindoles and -indolines having serotonin 5-ht2c activity
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
JP5173190B2 (ja) 2004-08-25 2013-03-27 武田薬品工業株式会社 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
CN101404882A (zh) * 2006-01-19 2009-04-08 阿特西斯公司 作为5-羟色胺5-HT2c受体配体的噻吩基和吡咯基氮杂类及其用途
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
EP3663294A1 (en) 2007-03-12 2020-06-10 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
MX2010007430A (es) 2008-01-11 2010-12-21 Albany Molecular Res Inc Piridoindoles (1-azinona)-sustituidos como antagonistas de la hormona de concentracion melanina humana.
WO2010124042A2 (en) * 2009-04-23 2010-10-28 Abbott Laboratories Modulators of 5-ht receptors and methods of use thereof
US8618299B2 (en) 2009-07-01 2013-12-31 Albany Molecular Research, Inc. Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
WO2011003021A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
EP2448585B1 (en) 2009-07-01 2014-01-01 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
US8629158B2 (en) 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011071136A1 (ja) 2009-12-11 2011-06-16 アステラス製薬株式会社 線維筋痛症治療剤
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
US9428506B2 (en) 2012-04-14 2016-08-30 Intra-Cellular Therapies, Inc. Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders
EP2968320B1 (en) 2013-03-15 2020-11-11 Intra-Cellular Therapies, Inc. Organic compounds
HUE056496T2 (hu) 2013-12-03 2022-02-28 Intra Cellular Therapies Inc Eljárás skizofrénia reziduális szimptómáinak kezelésére
MX365969B (es) 2014-04-04 2019-06-21 Intra Cellular Therapies Inc Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio.
CA2944755A1 (en) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
AU2017211791B2 (en) 2016-01-26 2022-01-06 Intra-Cellular Therapies, Inc. Organic compounds
EP3436016B1 (en) 2016-03-28 2022-04-27 Intra-Cellular Therapies, Inc. Novel co-crystals
JP2019513143A (ja) 2016-03-28 2019-05-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規塩類および結晶
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
CN105837571A (zh) * 2016-04-23 2016-08-10 何华琼 盐酸倍他司汀的药物组合物及其在生物医药中的应用
US11331316B2 (en) 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
WO2018126143A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
MX2021013640A (es) 2017-03-24 2022-08-31 Intra Cellular Therapies Inc Composiciones novedosas y metodos.
US11376249B2 (en) 2017-07-26 2022-07-05 Intra-Cellular Therapies, Inc. Organic compounds
JP7224333B2 (ja) 2017-07-26 2023-02-17 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
WO2019241278A1 (en) 2018-06-11 2019-12-19 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
US11957791B2 (en) 2018-08-31 2024-04-16 Intra-Cellular Therapies, Inc. Methods
EP3843739A4 (en) 2018-08-31 2022-06-01 Intra-Cellular Therapies, Inc. NEW METHODS
EP3931189A4 (en) 2019-02-27 2022-11-30 The Regents Of The University Of California AZEPINO-INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839357A (en) * 1966-05-10 1974-10-01 Upjohn Co 1,2,3,4,5,6-hexahydroazepino(4,5-b)indoles
US3676558A (en) * 1970-08-28 1972-07-11 Upjohn Co Anorexigenic compositions comprising 6-alkyl-1,2,3,4,5,6-hexahydroazepino 4,5-indoles as active ingredient and process of treatment
EP0377238A1 (en) * 1988-12-22 1990-07-11 Duphar International Research B.V New annelated indolo (3,2-c)-lactams

Also Published As

Publication number Publication date
HK1045512A1 (en) 2004-10-15
EP1173440B1 (en) 2004-09-15
AU760943C (en) 2003-12-04
ZA200108636B (en) 2003-02-19
ATE276255T1 (de) 2004-10-15
CA2367682A1 (en) 2000-11-02
DK1173440T3 (da) 2004-12-20
NZ514553A (en) 2003-10-31
CN1348454A (zh) 2002-05-08
ECSP003426A (es) 2000-10-24
DE60013803D1 (de) 2004-10-21
DE60013803T2 (de) 2005-11-17
EP1173440A1 (en) 2002-01-23
JP2002543080A (ja) 2002-12-17
HK1045512B (zh) 2005-09-02
AU4363700A (en) 2000-11-10
CN1183132C (zh) 2005-01-05
ES2226822T3 (es) 2005-04-01
BR0009983A (pt) 2002-04-16
SI1173440T1 (en) 2005-02-28
AU760943B2 (en) 2003-05-22
AR023574A1 (es) 2002-09-04
PT1173440E (pt) 2004-12-31
WO2000064899A1 (en) 2000-11-02
KR20020005708A (ko) 2002-01-17

Similar Documents

Publication Publication Date Title
PE20010052A1 (es) Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht
Chu et al. Structure-activity relationships of the fluoroquinolones
RU2404163C2 (ru) Производные 2,3,4,9-тетрагидро-1h-карбазола в качестве антагонистов рецептора crth2
KR920701204A (ko) 중추 신경계 활성을 갖는 헤테로사이클릭 아민
PE20090718A1 (es) Derivados de espiroindolinona
RU2496775C2 (ru) Соединение бензодиазепина и фармацевтическая композиция
PE20030848A1 (es) Compuestos de espiropiperidina n-sustituidos como ligandos para el receptor orl-1
JP6843979B2 (ja) 新規なビフェニル化合物又はその塩
PE20110671A1 (es) Derivados de diazabicicloalcanos como moduladores de la actividad de los receptores nicotinicos de la acetilcolina
AR037731A1 (es) Uso de ureas de benzotiazoles
WO2014179528A2 (en) Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions
AR035774A1 (es) Derivados benzimidazol y piridilimidazol, un procedimiento para su preparacion, composiciones farmaceuticas y paquetes que los comprenden, el uso de dichos compuestos solos o en combinacion para la manufactura de medicamentos como ligandos para gabaa, y metodo de tratamiento
AR067662A1 (es) Derivados de benzo[d]isoxazol-3-il-piperidina, medicamentos que los contienen y usos terapeuticos para enfermedades asociadas al sistema nervioso.
AR040566A1 (es) Derivados de 1-heterociclilalquil 3- sulfonilazaindol o azaindazol como ligandos de 5 hidroxitriptamina-6
PE20040593A1 (es) DERIVADOS DE DIHIDROPIRIMIDO[4,5-d]PIRIMIDONA AMINO SUSTITUIDOS COMO INHIBIDORES DE TIROSINACINASAS DEL GRUPO SRC
PE20020485A1 (es) Derivados de quinolina y quinazolina como antagonistas del neuropeptido y
PE20081346A1 (es) Derivados de espiroindolinona como antagonistas de mdm2
AR029454A1 (es) Derivados de piperazina sustituidos, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de medicamentos
BR0309463A (pt) Derivados de 1,2,3,4,7,8-hexaidro-6h-[1,4]diazepino[6,7,1-ij]quinolina como agentes antipsicóticos e antiobesidade
PE20060653A1 (es) Derivados triciclicos condensados como moduladores del receptor 5-ht1
AR045762A1 (es) Derivados de quinazolina
PE20060383A1 (es) Nuevos derivados amino de urea ciclicos como inhibidores de quinasa
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina
AR049664A1 (es) Metodos anticonceptivos con antagonistas del receptor de progesterona derivados del indol y de la benzo[d][1, 3]oxazina y kits.
AR043181A1 (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxiptamina-6

Legal Events

Date Code Title Description
FC Refusal